This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Aorticstenosis is a narrowing of the aorticvalve which prevents the aortic leaflets from opening and closing properly. As a result, the heart must work "over time" to pump blood throughout the body. Without treatment, up to 50% of patients will die 24 months after the onset of symptoms1.
22, 2025More than 60,000 people die from heartvalve disease (HVD) in the U.S. each year, according to the American Heart Association 2025 Heart Disease and Stroke Statistical Update. This year on HeartValve Disease Awareness Day (Feb. tim.hodson Tue, 03/04/2025 - 14:11 Feb.
IntroductionSince TAVR was approved for lower-risk aorticstenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heartvalves (SEV).
AorticStenosis (AS) is a common condition with an estimated pooled prevalence of all AS in the elderly population at around 12.4%, with that of severe AS estimated to be around 3.4%. In the past, surgical aorticvalve replacement was the primary treatment option for severe AS for decades.
The global, randomized trial ( envisiontrial.com ) will evaluate the safety and effectiveness of Abbott’s minimally invasive Navitor transcatheter aorticvalve implantation (TAVI) system in approximately 1,500 patients at intermediate or low surgical risk with severe aorticstenosis (narrowing of the aorticvalve).
IntroductionClinical evidence highlighting the efficacy and safety of transcatheter aorticvalve replacement (TAVR) and the 2019 Food and Drug Administration (FDA) approval for TAVR in low-risk (younger) patients has created a demand for durable and long-lasting bioprosthetic heartvalve (BHV) leaflet materials.
Aorticstenosis is a narrowing of the aorticvalve which prevents the aortic leaflets from opening and closing properly. As a result, the heart must work "over time" to pump blood throughout the body. Without treatment, up to 50% of patients will die 24 months after the onset of symptoms1.
In all cases, patients achieved complete resolution of aortic disease with no residual stenosis or regurgitation immediately following the procedure, and all patients were discharged within 24-48 hours of the procedure.
Some patients with aorticstenosis may require multiple valve interventions in their lifetime, and choosing transcatheter aorticvalve replacement (TAVR) as the initial intervention may be appealing to many. If their transcatheter heartvalve degenerates later in life, most will hope to undergo redo-TAVR.
This next-generation surgical aortic tissue valve is designed to facilitate ease of use at implant and lifetime patient management. It’s an excellent choice for cardiac surgeons and their patients seeking an aorticvalve solution that can be fit for the future, right from the start. February 18–21, 2024.
This next-generation surgical aortic tissue valve is designed to facilitate ease of use at implant and lifetime patient management. It’s an excellent choice for cardiac surgeons and their patients seeking an aorticvalve solution that can be fit for the future, right from the start. February 18–21, 2024.
Recent findings from a study on a transcatheter heartvalve (THV) system, which includes a new class of transcatheter aorticvalve, showed positive results in the device's ability to function as a healthy and natural aorticvalve in patients with aorticstenosis (AS).
Background Cardiovascular MRI is advantageous in transcatheter aorticvalve implantation (TAVI) planning. Methods Thirty patients with severe aorticstenosis were prospectively enrolled. Transcatheter heartvalve (THV) sizing was performed based on CCTA measurements and compared with 3D whole-heart MRI measurements.
Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heartvalve, for which more than 1.6 Abbott continues to focus on addressing the unmet needs of patients with structural heart disease and advancing standards of care so people can live their fullest possible lives.
BACKGROUND:Data concerning the outcomes of transcatheter aorticvalve replacement in type 0 bicuspid aorticstenosis (AS) are scarce. Self-expanding transcatheter heartvalves were used in the majority of patients (n=1160; 91.4%). In the matched population, differences in mortality (30 days: 4.2%
reported results from a clinical study of revolutionary earbuds that use a new technology - In-ear Infrasonic Hemodynography to Detects AorticStenosis Murmur Before and After Transcatheter AorticValve Replacement (TAVR). milla1cf Tue, 12/26/2023 - 21:36 December 26, 2023 — MindMics, Inc. the R&D Manager of MindMics.
Transcatheter aorticvalve replacement (TAVR) is increasingly being performed in younger and lower surgical risk patients. Reintervention for failed transcatheter heartvalves will likely increase in the future as younger patients are expected to outlive the initial bioprosthesis.
The goal of the LANDMARK trial was to evaluate transcatheter aorticvalve replacement (TAVR) with the Myval prosthesis compared with a contemporary prosthesis among patients with symptomatic severe aorticstenosis.
In this scientific statement, we review the basic cellular structures of the human heartvalves and discuss how these structures change in primary valvular heart disease.
Introduction Severe aorticstenosis is a major cause of morbidity and mortality. The existing treatment pathway for transcatheter aorticvalve implantation (TAVI) traditionally relies on tertiary HeartValve Centre workup. Methods The centre performing local workup implemented a novel TAVI referral pathway.
In light of the growing number of patients undergoing transcatheter aorticvalve replacement (TAVR), there is an increasing demand for data regarding the management of failed TAVR procedures, including the possibility of a repeat TAVR intervention. No significant disparities were found in the rates of death at 30 days (4.7%
During the procedure, you’ll be hooked up to a heart-lung bypass machine so that your blood flow can be maintained throughout the surgery Types Of Minimally Invasive Heart Surgery If minimally invasive heart surgery is an option for you, you’ll work with a surgeon to determine the ideal one.
A cost-effectiveness analysis demonstrates the positive economic value of transcatheter aorticvalve replacement (TAVR) using Evolut TAVR compared to surgical aorticvalve replacement (SAVR) for low-risk patients. At Medtronic, we continue to emphasize that valve design matters. mmHg TAVR; 11.8
A study led by bioengineers at the University of California San Diego sheds new light on how a type of heartvalve disease, called aorticvalvestenosis, progresses differently in males and females. The research reveals that this sex-based difference can be traced to a gene on the Y chromosome.
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
Program Designations Access and Publications (A&P) 1 Participant User File (PUF) 2 Task Force on Funded Research (TFR) 3 Special Projects 4 Adult Cardiac Surgery Database Lead Author Title Publication Date William Keeling 2 National Trends in Emergency Coronary Artery Bypass Grafting European Journal of Cardiothoracic Surgery October 2023 Jake (..)
In patients undergoing transcatheter aorticvalve implantation (TAVI), multi-valve disease is common and associated with worse outcomes. Despite multiple emerging transcatheter valve treatment options, no guidelines exist for the transcatheter treatment of multi-valve disease.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content